Krystal Biotech Stock Forecast, Price & News

Krystal Biotech (NASDAQ:KRYS) Frequently Asked Questions

Is Krystal Biotech a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Krystal Biotech stock.
View analyst ratings for Krystal Biotech or view top-rated stocks.

How has Krystal Biotech's stock been impacted by Coronavirus (COVID-19)?

Krystal Biotech's stock was trading at $49.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KRYS shares have increased by 10.8% and is now trading at $55.29.
View which stocks have been most impacted by COVID-19.

Are investors shorting Krystal Biotech?

Krystal Biotech saw a drop in short interest during the month of December. As of December 31st, there was short interest totaling 1,030,000 shares, a drop of 25.4% from the December 15th total of 1,380,000 shares. Based on an average daily volume of 430,400 shares, the days-to-cover ratio is currently 2.4 days. Currently, 5.4% of the company's stock are sold short.
View Krystal Biotech's Short Interest.

When is Krystal Biotech's next earnings date?

Krystal Biotech is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Krystal Biotech.

How were Krystal Biotech's earnings last quarter?

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Sunday, November, 7th. The company reported ($0.70) EPS for the quarter, topping the Zacks' consensus estimate of ($0.76) by $0.06.
View Krystal Biotech's earnings history.

What price target have analysts set for KRYS?

6 Wall Street analysts have issued twelve-month price targets for Krystal Biotech's stock. Their forecasts range from $97.00 to $125.00. On average, they anticipate Krystal Biotech's stock price to reach $114.00 in the next twelve months. This suggests a possible upside of 106.2% from the stock's current price.
View analysts' price targets for Krystal Biotech or view top-rated stocks among Wall Street analysts.

Who are Krystal Biotech's key executives?

Krystal Biotech's management team includes the following people:

• Krish S. Krishnan, Chairman, President & Chief Executive Officer
• Suma M. Krishnan, Chief Operating Officer & Director
• Stacie Oliver, Clinical Affairs Scientist
• George Chen, Manager-Information Technology & CSV
• Trevor Parry, Senior Director-Scientific Affairs

Who are some of Krystal Biotech's key competitors?

Some companies that are related to Krystal Biotech include CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Abcam (ABCM), Ablynx (ABLYF), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT) and Bavarian Nordic A/S (BVNRY).
View all of KRYS's competitors.

What other stocks do shareholders of Krystal Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

When did Krystal Biotech IPO?

(KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

What is Krystal Biotech's stock symbol?

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Who are Krystal Biotech's major shareholders?

Krystal Biotech's stock is owned by a number of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%), DNB Asset Management AS (0.16%), Parallel Advisors LLC (0.15%) and HighMark Wealth Management LLC (0.08%).
View institutional ownership trends for Krystal Biotech.

Which institutional investors are selling Krystal Biotech stock?

KRYS stock was sold by a variety of institutional investors in the last quarter, including HighMark Wealth Management LLC.
View insider buying and selling activity for Krystal Biotech or view top insider-selling stocks.

Which institutional investors are buying Krystal Biotech stock?

KRYS stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Cutler Group LP, and Parallel Advisors LLC.
View insider buying and selling activity for Krystal Biotech or or view top insider-buying stocks.

How do I buy shares of Krystal Biotech?

Shares of KRYS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Krystal Biotech's stock price today?

One share of KRYS stock can currently be purchased for approximately $55.29.

How much money does Krystal Biotech make?

Krystal Biotech has a market capitalization of $1.23 billion. The company earns $-32.17 million in net income (profit) each year or ($2.71) on an earnings per share basis.

How many employees does Krystal Biotech have?

Krystal Biotech employs 75 workers across the globe.

What is Krystal Biotech's official website?

The official website for Krystal Biotech is www.krystalbio.com.

Where are Krystal Biotech's headquarters?

Krystal Biotech is headquartered at 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203.

How can I contact Krystal Biotech?

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The company can be reached via phone at (412) 586-5830 or via email at [email protected].